{{Rsnum
|rsid=1799929
|Gene=NAT2
|Chromosome=8
|position=18400484
|Orientation=plus
|ReferenceAllele=C
|GMAF=0.2773
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=NAT2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 36.6 | 46.4 | 17.0
| HCB | 94.9 | 5.1 | 0.0
| JPT | 94.7 | 5.3 | 0.0
| YRI | 71.0 | 24.8 | 4.1
| ASW | 59.6 | 31.6 | 8.8
| CHB | 94.9 | 5.1 | 0.0
| CHD | 89.9 | 8.3 | 1.8
| GIH | 51.0 | 41.0 | 8.0
| LWK | 46.8 | 43.1 | 10.1
| MEX | 40.4 | 45.6 | 14.0
| MKK | 28.4 | 54.2 | 17.4
| TSI | 31.7 | 47.5 | 20.8
| HapMapRevision=28
}}[[rs1799929]] is a SNP in the [[NAT2]] gene, potentially encoding a variant detoxifying protein known as an N-acetyltransferase, but which [[NAT2]] variant depends on which other [[NAT2]] SNPs were also inherited. See the discussion of the [[NAT2]] gene for a more complete explanation.

The risk allele for this SNP is [[rs1799929]](T).

When this SNP is indicative of carrying a NAT2*5A allele, the following may be relevant:

A study (based on only 42 patients) found that women with the NAT2*5A slow genotype (which presumably means [[rs1799929]](T;T)) had a significantly higher risk of [[cervical cancer]] compared with individuals with the NAT2*5A fast genotype (i.e. carriers of only one [[rs1799929]](T) allele), with a reported odds ratio of 7.469 (CI: 1.6-33.3, p=0.008).{{PMID|19823052}}

{{ neighbor
| rsid = 1801280
| distance = 140
}}
{{ neighbor
| rsid = 1799930
| distance = 109
}}

{{PharmGKB
|RSID=rs1799929
|Name_s=NAT2:481C>T, one of 3 variants comprising NAT2*5B
|Gene_s=NAT2
|Feature=
|Evidence=PubMed ID:19356010
|Annotation=in vitro study; PK: 20-fold reduction in Vmax vs wild type
|Drugs=clonazepam
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110590
}}

{{PharmGKB
|RSID=rs1799929
|Name_s=NAT2:481C>T; included in NAT2*5A, NAT2*5B, NAT2*5F, NAT2*5G, NAT2*5H, NAT2*5I, NAT2*6E, NAT2*11A, NAT2*11B, NAT2*12C, NAT2*14C. T allele defines "M1"(older nomenclature).
|Gene_s=NAT2
|Feature=
|Evidence=PubMed ID:17434923; PubMed ID:7668286; PubMed ID:7920692; Web Resource:http://louisville.edu/medschool/pharmacology/Human.NAT2.pdf
|Annotation=May be important for acetylator phenotype (altered rates of metabolism of arylamines), but which allele is associated with rapid/slow is controversial.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145097
}}

{{PMID Auto
|PMID=22092036
|Title=Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes
|OA=1
}}

{{PMID Auto
|PMID=14724163
|Title=Analysis of candidate modifier loci for the severity of colonic familial adenomatous polyposis, with evidence for the importance of the N-acetyl transferases.
|OA=1
}}

{{PMID Auto
|PMID=16112301
|Title=NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
|OA=1
}}

{{PMID Auto
|PMID=16416399
|Title=Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes.
|OA=1
}}

{{PMID Auto
|PMID=16847422
|Title=Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma.
|OA=1
}}

{{PMID Auto
|PMID=17160896
|Title=Orofacial cleft risk is increased with maternal smoking and specific detoxification-gene variants.
|OA=1
}}

{{PMID Auto
|PMID=17335581
|Title=Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus.
|OA=1
}}

{{PMID Auto
|PMID=18547414
|Title=Genotyping panel for assessing response to cancer chemotherapy.
|OA=1
}}

{{PMID Auto
|PMID=18664443
|Title=Unraveling ambiguous NAT2 genotyping data.
}}

{{PMID Auto
|PMID=18680467
|Title=Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.
|OA=1
}}

{{PMID Auto
|PMID=18773084
|Title=Multiple advantageous amino acid variants in the NAT2 gene in human populations.
|OA=1
}}

{{PMID Auto
|PMID=19766908
|Title=Association of NAT2 gene polymorphisms with susceptibility to esophageal and gastric cancers in the Kashmir Valley.
}}

{{PMID Auto
|PMID=20043821
|Title=Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data.
|OA=1
}}

{{PMID Auto
|PMID=22137356
|Title=An unlikely role for the NAT2 genotypes and haplotypes in the oral cancer of south Indians.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1799929
|overall_frequency_n=4001
|overall_frequency_d=10758
|overall_frequency=0.371909
|n_genomes=26
|n_genomes_annotated=0
|n_haplomes=32
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=24928356
|Title=Synergism between the N-acetyltransferase 2 gene and oxidant exposure increases the risk of idiopathic male infertility
}}

{{PMID Auto
|PMID=25017831
|Title=N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}